ArticleiMeta2026
Hyperoside alleviates endometrial stromal cell senescence in unexplained recurrent spontaneous abortion via DHX9-mediated R-loop resolution.
Article in iMeta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Decidualization deficiency is a hallmark pathology of unexplained recurrent spontaneous abortion (URSA), but the undefined molecular drivers hinder the development of effective therapies. Hyperoside, a bioactive flavonoid from Hypericum perforatum, exhibits therapeutic potential against URSA, yet its underlying mechanism of action remains unknown. In this study, we employed an integrated multi-omics approach coupled with a multi-dimensional validation framework that spanned URSA patient decidual tissues, in vivo mouse models, and in vitro telomerase-immortalized human endometrial stromal cell (T-hESC) decidualization system, to systematically investigate hyperoside's mechanism in URSA, with a focus on R-loop-driven endometrial stromal cell senescence. We found that hyperoside dose-dependently reduced embryo resorption and rescued decidualization deficiency by preventing stromal cell senescence. Mechanistically, hyperoside effectively alleviated aberrant intracellular R-loop accumulation, thereby suppressing excessive activation of the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway which contributes to the initiation of the cellular senescence program. Further target identification and validation experiments confirmed that DExH-box helicase 9 (DHX9) was the functional molecular target of hyperoside, with the Thr419 residue serving as the critical binding site. Functional validation revealed that DHX9 knockdown or introduction of the T419A point mutation markedly attenuated the anti-senescence and pro-decidualization effects of hyperoside. In vivo experiments further confirmed that uterine-specific knockdown of DHX9 reduced hyperoside's protective effects against R-loop accumulation, cGAS-STING pathway activation, and embryo loss. Collectively, these findings demonstrate that hyperoside alleviates stromal cell senescence and decidualization deficiency in URSA through DHX9-dependent resolution of R-loops and subsequent suppression of cGAS-STING-associated senescence signaling. More broadly, this work identifies R-loop-mediated genomic stress as a previously underappreciated contributor to URSA-associated decidual dysfunction and provides a mechanistic basis for the protective effects of hyperoside through DHX9-dependent R-loop homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.